This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
A couple of days after announcing that has pulled out of its planned $8.1 billion acquisition of two of Abbott’s diagnostics divisions, GE officials suggested during a conference call that it was highly unlikely that the firm would make any acquisitions this year costing more than $2 billion.